# China NMPA Product Recall - Compound Zinc Undecanoate Triamcinolone Ointment

Source: https://www.globalkeysolutions.net/records/china_product_recall/wuhu-sanyi-xincheng-pharmaceutical-co-ltd/a2582889-1c9f-45a4-9b0d-266a7fea2159/
Source feed: China

> China NMPA product recall for Compound Zinc Undecanoate Triamcinolone Ointment by Wuhu Sanyi Xincheng Pharmaceutical Co., Ltd. published April 28, 2011. Recall level: . The National Medical Products Administration (NMPA) initiated a recall against Wuhu Sanyi Xincheng P

---

## Details

- Record Type: CHINA_PRODUCT_RECALL
- Title: The Wuhu Municipal Food and Drug Administration of Anhui Province ordered Wuhu Sanyi Xincheng Pharmaceutical Co., Ltd. to recall its Zinc Undecanoate Triamcinolone Ointment.
- Company Name: Wuhu Sanyi Xincheng Pharmaceutical Co., Ltd.
- Publication Date: 2011-04-28
- Product Name: Compound Zinc Undecanoate Triamcinolone Ointment
- Recall Reason: Suspected of illegal production
- Discovering Company: Anhui Provincial Food and Drug Administration
- Manufacturing Company: Wuhu Sanyi Xincheng Pharmaceutical Co., Ltd.
- Summary: The National Medical Products Administration (NMPA) initiated a recall against Wuhu Sanyi Xincheng Pharmaceutical Co., Ltd., publicized on April 28, 2011. This decision stemmed from a report by the Anhui Provincial Food and Drug Administration, which identified suspected regulatory violations in the company's production of Compound Zinc Undecenoate Triamcinolone Ointment. Although the specific nature of the production non-compliance was not detailed, the findings prompted the Wuhu Municipal Food and Drug Administration to issue a direct order for the recall of all affected Compound Zinc Undecenoate Triamcinolone Ointment manufactured and distributed by the company. This action aligns with the NMPA's regulatory framework for ensuring pharmaceutical product safety and quality within China. Furthermore, Food and Drug Administrations across all jurisdictional levels were mandated to intensify their oversight and management of the recall process. They were also instructed to report any additional non-compliant activities discovered during the recall, underscoring the commitment to upholding public health standards and regulatory compliance in pharmaceutical manufacturing. The primary objective of the recall is to address potential risks associated with the non-compliant product and safeguard consumer well-being.

Company: https://www.globalkeysolutions.net/companies/wuhu-sanyi-xincheng-pharmaceutical-co-ltd/7a5f1425-4415-47d1-8c50-6116f0659d2c/